Investigating new therapies for spinal muscular atrophy
Official title: Mechanisms and SMN-Independent Therapies for Spinal Muscular Atrophy
Funded at Columbia University Health Sciences · NIH-11059216 · Data updated 2026-11-12
This study is looking at new ways to help people with spinal muscular atrophy (SMA) by exploring treatments that go beyond just fixing the SMN protein, aiming to find better options for young patients with this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | April 1, 2022 |
| Project end | March 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $435,905 |
| NIH project number | 5R01NS123292-04 |
| Project ID | NIH-11059216 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are infants and young children diagnosed with spinal muscular atrophy, particularly those under the age of two.
✕Less likely to help
Patients with spinal muscular atrophy who are older or have already progressed to advanced stages of the disease may not benefit from this research.
What this research studies
This research focuses on understanding the mechanisms behind spinal muscular atrophy (SMA), a severe neuromuscular disorder caused by mutations in the SMN1 gene. The project aims to explore therapies that do not rely solely on the SMN protein, including small molecule modulators and viral vector approaches to restore SMN levels. By studying the underlying causes of SMA, the research seeks to improve treatment strategies and outcomes for affected individuals, particularly those diagnosed at a young age.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for spinal muscular atrophy, potentially improving survival and quality of life for patients.
How similar studies have gone: Previous research has shown promise in targeting the SMN2 gene for SMA treatment, indicating that exploring alternative therapies could also yield beneficial results.
Where this research is happening
-
Columbia University Health Sciences
New York, United States Active
Researchers
- Principal investigator: Monani, Umrao — Columbia University Health Sciences
- Study coordinator: Monani, Umrao
Related research
Other NIH-funded projects on the same topics.
-
Genetic clues to mouth muscles development in SMA
A small NIH grant studies how nerve cells controlling jaw movements develop normally and how this process goes wrong in spinal muscular atrophy (SMA).
-
Therapeutic gene editing for spinal muscular atrophy
A patient-facing look at a project that aims to test a gene-editing approach to help children with spinal muscular atrophy.
-
SMN-independent approaches for spinal muscular atrophy
This project looks for new treatments for people with spinal muscular atrophy that work without relying only on restoring the SMN protein.
-
How RNA problems cause nerve and muscle damage in spinal muscular atrophy
This project looks at how RNA-related problems lead to nerve and muscle damage in people with spinal muscular atrophy to help find better treatment targets.
-
Investigating speech development in children with spinal muscular atrophy after new therapies
This study is looking at how new treatments for spinal muscular atrophy (SMA) can help improve speech and communication skills in children and young adults aged 2 to 21, by comparing their speech abilities to what’s expected for their age.
-
Correcting Genetic Errors for Spinal Muscular Atrophy
This research looks for new ways to fix the genetic problem that causes Spinal Muscular Atrophy, a condition that weakens muscles.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.